Group I intron-based trans-splicing ribozyme specifically recognizes disease-specific RNA, removes the sequence downstream of the target site, and replaces it with a 3’-exon encoding a therapeutic/reporter RNA sequence, inducing therapeutic/reporter activity selectively in the target RNA-expressing cells.
